herpes simplex
Conditions
Interventions
Lactating patients with a history of recurrent herpes simplex will receive a PIT prescription for AMNV at the practicing institution, and patients will receive a single oral dose of 1200 mg of AMNV po
Sponsors
Koinuma sachi
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients with a previous diagnosis of recurrent herpes simplex 2) Patients with at least 1 recurrence of herpes simplex in the past 1 year 3) Patients who are breast-feeding within 1 year after delivery at the time of consent 4) Patients who are between 18 and 47 years of age at the time of consent 5) Patients weighing between 40 and 70 kg at the time of consent 6) Patients who are judged by the principal investigator or a research associate to be able to abstain from breastfeeding for 48 hours after taking AMNV 7) Patients who freely and voluntarily consent to participate in this study in writing.
Exclusion criteria
Exclusion criteria: 1) Patients who have ingested drugs, foods, or beverages listed in the Contraindications or Precautions section of the AMNV package insert within 14 days prior to obtaining consent 2) Patients requiring dietary restrictions due to comorbidities, etc. 3) Patients on extreme diet restrictions due to dieting, etc. 4) Patients with a history of hypersensitivity to AMNV 5) Patients with diabetes mellitus, hepatitis B or C, tuberculosis, mastitis, comorbidity or history of malignancy 6) Patients with a history of HIV infection or comorbidity or history of AIDS 7) Patients who are pregnant or may become pregnant, or who wish to become pregnant during the study period 8) Other patients deemed ineligible by the principal investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RID calculated using milk drug concentration Cave[AUC (0, 24h)] when AMNV is taken | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) RID calculated using the Cmax concentration of the drug in milk when AMNV is taken 2) RID calculated using the milk drug concentration Cave[AUC (0, 48h)] when taking AMNV 3) Plasma drug concentration of AMNV 4) Frequency and rate of adverse events | — |
Contacts
Public ContactSachi Koinuma
National Center for Child Health and Development
Outcome results
None listed